Instructions for Polydexa with phenylephrine spray 15 ml
Pharmacological properties
A combination formulation for topical use in otorhinolaryngology. The therapeutic effect of the preparation Polydex with phenylephrine is due to the anti-inflammatory effect of dexamethasone on the nasal mucosa, the antimicrobial effect of the antimicrobial neomycin and polymyxin B and the vasoconstrictive effect of phenylephrine. With the combination of these antimicrobial, the spectrum of antimicrobial action is expanded to most gram-positive and gram-negative microorganisms that cause infectious-inflammatory diseases of the nasal cavity and paranasal sinuses. Due to the vasoconstrictive action of phenylephrine, nasal congestion is reduced and nasal respiration is facilitated. Systemic resorption of the drug Polydexa is minimal.
Indications:
Inflammatory and infectious diseases of the nasal cavity, paranasal sinuses, including acute rhinitis, acute sinusitis.
Application:
Adults are prescribed 3-5 injections per day in each nasal passage, children aged 12 to 15 years - 3 injections per day in each nasal passage for 5-10 days.
Contraindications:
Children under 12 years of age, hypersensitivity to the components of the drug Polydexa, herpetic infection of nasal localization, chickenpox, pregnancy and breastfeeding, simultaneous use of guanetidine or similar drugs, bromocriptine, MAO inhibitors and drugs Polydexa capable of causing corresponding changes on ECG (see INTERACTIONS).
Side effects:
Local: in some cases, a feeling of dry nose is possible, local allergic reactions such as urticaria, itching. Systemic side effects are possible only with prolonged treatment (longer than the prescribed period) or with use at a dose significantly exceeding the recommended one.
Systemic: headache, insomnia, increased BP, tachycardia, tremor, paleness of the skin. Sensitization to antimicrobial included in the drug is possible.
Special instructions:
The drug should not be swallowed.
This drug Polydexa cannot be used longer than the prescribed period (10 days).
The presence of a corticosteroid in the formulation does not prevent local allergy symptoms, but can alter their course.
If the general condition deteriorates due to an infectious-inflammatory disease, antimicrobial are prescribed for systemic use if necessary.
With caution, patients with AG, CHD, hyperthyroidism are prescribed due to the presence of sympathomimetic in the drug Polydexa.
The drug contains dexamethasone, which can give a positive result during doping control.
Despite the topical use of the drug Polydexa, it should be noted that with long-term therapy or with a dose significantly exceeding the recommended one, the drug can have a systemic effect.
With the systemic action of the active components of the drug, their interaction with other drugs Polydexa is possible.
Interactions:
The following are features of drug Polydexa interaction arising from systemic absorption of active components of the preparation.
Phenylephrine-specific interactions
Unacceptable combinations: with bromocriptine (risk of developing AG); with guanetidine or substances similar in chemical structure (the possibility of enhancing the hypertensive effect of phenylephrine and, due to a decrease in the sympathetic tone of guanetidine, the possibility of prolonged midriasis); MAO inhibitors (possible development of hypertensive crisis due to weakening of the metabolism of pressor amines). Due to the prolonged action of MAO inhibitors, the interaction is possible within 2 weeks after the withdrawal of MAO inhibitors.
Interactions specific to dexamethasone
Unacceptable combinations: with drugs that can cause changes to ECG (astemisole, bepridyl, erythromycin IV, halophantrine, pentamidine, sparfloxacin, sultopride, terfenadine and vincamine). Hypokalemia, bradycardia, and increased Q-T interval may be adverse factors.
Combinations that require special care: prolonged systemic use of acetylsalicylic acid and other salicylates (a decrease in serum salicylate levels with GCS and the risk of salicylate overdose after GCS withdrawal are possible); antiarrhythmic agents that can cause changes to ECG (amiodarone, bretilium, dizopyramide, quinidine, sotalol) - hypokalemia, bradycardia and an increase in the Q-T interval on ECG are possible; indirect anticoagulants (the possibility of the effect of GCS on the metabolism of indirect anticoagulants and coagulation factors, which can increase the risk of bleeding specific for systemic GCS therapy - gastrointestinal, due to vascular fragility); drugs that reduce serum potassium levels (diuretics, laxatives, amphotericin B/b) lead to an increased risk of hypokalemia; napkin preparations (hypokalemia enhances the toxic effects of napkin preparations); heparin (increases the risk of hemorrhagic complications characteristic of GCS); insulin, metformin (reduced efficacy of hypoglycemia drugs, which can lead to the development of ketosis due to GCS-induced decrease in glucose tolerance); isoniazid (reducing plasma isoniazid levels).
Combinations that require caution: antihypertensive agents (possible weakening of the antihypertensive effect); weakened live vaccines (risk of disease generalization up to death); praziquantel (possibly reduced plasma praziquantel concentration).
Overdose:
Due to the low degree of absorption into the systemic bloodstream, an overdose is unlikely.
Storage conditions:
At temperature up to 25 ° С.
